169 related articles for article (PubMed ID: 18071984)
1. Proteomic analysis of gliomas.
Whittle IR; Short DM; Deighton RF; Kerr LE; Smith C; McCulloch J
Br J Neurosurg; 2007 Dec; 21(6):576-82. PubMed ID: 18071984
[TBL] [Abstract][Full Text] [Related]
2. Molecular classification and survival prediction in human gliomas based on proteome analysis.
Iwadate Y; Sakaida T; Hiwasa T; Nagai Y; Ishikura H; Takiguchi M; Yamaura A
Cancer Res; 2004 Apr; 64(7):2496-501. PubMed ID: 15059904
[TBL] [Abstract][Full Text] [Related]
3. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue.
Brown LM; Helmke SM; Hunsucker SW; Netea-Maier RT; Chiang SA; Heinz DE; Shroyer KR; Duncan MW; Haugen BR
Mol Carcinog; 2006 Aug; 45(8):613-26. PubMed ID: 16788983
[TBL] [Abstract][Full Text] [Related]
4. Proteomics of gliomas: initial biomarker discovery and evolution of technology.
Kalinina J; Peng J; Ritchie JC; Van Meir EG
Neuro Oncol; 2011 Sep; 13(9):926-42. PubMed ID: 21852429
[TBL] [Abstract][Full Text] [Related]
5. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
7. Multifarious proteomic signatures and regional heterogeneity in glioblastomas.
Park CK; Jung JH; Park SH; Jung HW; Cho BK
J Neurooncol; 2009 Aug; 94(1):31-9. PubMed ID: 19219580
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors.
Zheng PP; Luider TM; Pieters R; Avezaat CJ; van den Bent MJ; Sillevis Smitt PA; Kros JM
J Neuropathol Exp Neurol; 2003 Aug; 62(8):855-62. PubMed ID: 14503641
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method.
Zhao J; Fan YX; Yang Y; Liu DL; Wu K; Wen FB; Zhang CY; Zhu DY; Zhao S
Int J Clin Exp Pathol; 2015; 8(2):1535-44. PubMed ID: 25973038
[TBL] [Abstract][Full Text] [Related]
10. Proteomic identification of tumor biomarkers associated with primary gallbladder cancer.
Huang HL; Yao HS; Wang Y; Wang WJ; Hu ZQ; Jin KZ
World J Gastroenterol; 2014 May; 20(18):5511-8. PubMed ID: 24833881
[TBL] [Abstract][Full Text] [Related]
11. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry.
Schwartz SA; Weil RJ; Thompson RC; Shyr Y; Moore JH; Toms SA; Johnson MD; Caprioli RM
Cancer Res; 2005 Sep; 65(17):7674-81. PubMed ID: 16140934
[TBL] [Abstract][Full Text] [Related]
12. Biomarker discovery: a proteomic approach for brain cancer profiling.
Khalil AA
Cancer Sci; 2007 Feb; 98(2):201-13. PubMed ID: 17233837
[TBL] [Abstract][Full Text] [Related]
13. A unique four-hub protein cluster associates to glioblastoma progression.
Simeone P; Trerotola M; Urbanella A; Lattanzio R; Ciavardelli D; Di Giuseppe F; Eleuterio E; Sulpizio M; Eusebi V; Pession A; Piantelli M; Alberti S
PLoS One; 2014; 9(7):e103030. PubMed ID: 25050814
[TBL] [Abstract][Full Text] [Related]
14. Rapid Proteomic Profiling by MALDI-TOF Mass Spectrometry for Better Brain Tumor Classification.
Petre G; Durand H; Pelletier L; Poulenard M; Nugue G; Ray PF; Rendu J; Coutton C; Berger F; Bidart M
Proteomics Clin Appl; 2020 Sep; 14(5):e1900116. PubMed ID: 32198817
[TBL] [Abstract][Full Text] [Related]
15. Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique.
Banerjee HN; Mahaffey K; Riddick E; Banerjee A; Bhowmik N; Patra M
Mol Cell Biochem; 2012 Aug; 367(1-2):59-63. PubMed ID: 22547198
[TBL] [Abstract][Full Text] [Related]
16. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors.
Zhang R; Tremblay TL; McDermid A; Thibault P; Stanimirovic D
Glia; 2003 Apr; 42(2):194-208. PubMed ID: 12655603
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification.
Le Rhun E; Duhamel M; Wisztorski M; Gimeno JP; Zairi F; Escande F; Reyns N; Kobeissy F; Maurage CA; Salzet M; Fournier I
Biochim Biophys Acta Proteins Proteom; 2017 Jul; 1865(7):875-890. PubMed ID: 27890679
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer proteomics: a review for clinicians.
Galvão ER; Martins LM; Ibiapina JO; Andrade HM; Monte SJ
J Cancer Res Clin Oncol; 2011 Jun; 137(6):915-25. PubMed ID: 21465318
[TBL] [Abstract][Full Text] [Related]
20. Glioma pathophysiology: insights emerging from proteomics.
Deighton RF; McGregor R; Kemp J; McCulloch J; Whittle IR
Brain Pathol; 2010 Jul; 20(4):691-703. PubMed ID: 20175778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
